14.50
0.18 (1.26%)
| Penutupan Terdahulu | 14.32 |
| Buka | 14.61 |
| Jumlah Dagangan | 236,844 |
| Purata Dagangan (3B) | 223,219 |
| Modal Pasaran | 773,895,424 |
| Harga / Buku (P/B) | 4.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -1.63 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.89% |
| Nisbah Semasa (MRQ) | 22.78 |
| Aliran Tunai Operasi (OCF TTM) | -73.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -37.79 M |
| Pulangan Atas Aset (ROA TTM) | -19.00% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Tyra Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.25 |
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.69% |
| % Dimiliki oleh Institusi | 108.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alta Partners Management Company, L.P. | 30 Sep 2025 | 4,080,296 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Dec 2025 | Pengumuman | Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer |
| 12 Nov 2025 | Pengumuman | Tyra Biosciences Announces Participation at Upcoming Investor Events |
| 05 Nov 2025 | Pengumuman | Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |